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Sumnary In a study conducted at St Bartholomew's Hospital between 1972 and 1982, using moderately
intensive therapy (OPAL/HEAV'D), a low blast count at presentation (<10 x 10 1') and common ALL
(C-ALL) phenotype correlated favourably with duration of remission. Fifty-four patients (age range 15-57,
median 32) subsequently received a modification of the previous treatment programme which included
high-dose ara-C 2 g m-2 b.d. for 6 days as cycle 3 (OPAL + HD ARA-C). CR was achieved in 36/54 (67%)
patients, response correlating favourably with younger age (15-30 years vs 31-57 years, P = 0.02). Three
patients died in CR. Overall, there was no difference in survival or remission duration between patients who
received high dose ara-C and those in the control group. However, in contrast to the early results, there was a
reversal in the relevance of the prognostic factors with a trend in favour of high blast count (>10 x 109 1')
and T-cell phenotype in terms of remission duration. Moreover, comparison of duration of remission for the
previously defined prognostic groups according to therapy suggests that the prognosis of patients with 'high
risk' disease (T, B, null ALL or high blast count) is improved with more intensive therapy. In contrast, those
with 'low risk' disease (C-ALL and low blast count) have a better prognosis with less intensive therapy. These
observations confirm those of others and allow for individualisation of therapy on the basis of pre-treatment
variables.
Complete remission (CR) can be achieved in the majority of
adults with acute lymphoblastic leukaemia (ALL) with stand-
ard combination chemotherapy yet only a minority are cured
(Willemze et al., 1975, Hoelzer et al., 1984; Barnett et al.,
1986). Intensive consolidation therapy resulting in more
effective elimination of 'minimal residual disease' might thus
be expected to reduce the frequency of relapse.
Cytosine arabinoside (ara-C) in high doses, alone (Rudnick
et al., 1979; Herzig et al., 1983; Rohatiner et al., 1984;
Kantarjian et al., 1984; Marsh et al., 1987) and in combina-
tion with other drugs (Amadori et al., 1983, 1987; Capizzi et
al., 1984; Jones et al., 1985; Arlin et al., 1986; Stryckmans et
al., 1987; Hiddeman et al., 1987; Peters et al., 1987; Berman
et al., 1987) has been shown to induce remission in refractory
and recurrent ALL although the remissions are short lived.
Furthermore, it has been demonstrated that therapeutic levels
of ara-C can be maintained in the cerebro-spinal fluid after
systemic administration of the drug at high dosage (Slevin et
al., 1983). Thus 'high dose' ara-C might be exploited both as
systemic anti-leukaemic therapy and as potential central ner-
vous system (CNS) prophylaxis in patients with ALL.
Against this background, ara-C was incorporated into a
treatment programme for newly diagnosed patients with
ALL in the hope of prolonging remission duration and hence
survival. The results of this approach are presented below
and contrasted with the results of two earlier, less intensive
treatment programmes.
Materials and methods
Patients
Between January 1983 and October 1986, 54 newly diagnosed
patients were treated at three centres: St Bartholomew's Hos-
pital (SBH), London (30 patients), Ospedale Riuniti, Ber-
gamo and Ospedale San Bortolo, Vicenza (24 patients). Their
clinical characteristics are shown in Table I. Patients with a
blast count <10 x I1O'I in whom the phenotype was un-
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known (OPAL + HD ara-C, five patients, OPAL/HEAV'D,
19 patients) either because an aspirate could not be obtained
or, in the case of patients treated in 1972 and 1973 because
phenotyping was not done, are not included in Table I.
Comparison is made with the outcome for 111 patients
of similar age distribution treated at SBH between 1972
and 1982 with two treatment programmes, 'OPAL' and
'HEAV'D', as previously reported (Lister et al., 1978;
Barnett et al., 1986) and patients who subsequently received
'OPAL' between November 1986 and November 1987.
Details of these two regimens are shown in Table II.
Diagnosis
The morphological diagnosis was based on May-Grunwald-
Giemsa and cytochemical staining of bone marrow smears
which showed infiltration by at least 30% lymphoblasts. All
were classified according to the FAB system (Bennett et al.,
1976). Blast cells were isolated by standard density gradient
centrifugation and immunophenotyping studies performed
using a panel of monoclonal antibodies. A percentage bind-
Table I Clinical characteristics ofpatients in the 'high' and 'low' risk
groups at presentation
OPAL + HID
ARA-C OPAL/HEAV'D
'High' 'Low' 'High' 'Low'
Age
Range 15-57 15-57 15-58 16-52
Mean 32 34-69 30 29
Median 29 37 23 26
Absolute blast count
Range 0-355 0-9.1 0-435 0-9.5
Median 13.2 0.9 22 1.3
Phenotype
C 7 13 14 29
Null 13 - 23 -
B 5 6 -
T 9 - 15 -
Other I - 5 -
Not done I - -
Total 36 13 63 29
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Table II 'OPAL' and 'HEAV'D' regimens
'OPAL'
Drug Dose(m 2) (daily) Days Cycles
Adriamycin 30 mg 1 4
Vincristine 1.4mg 1 4
L-Asparaginase 10,000 units 1-14 1
Prednisolone 40mg until CR
'HEAV'D'
Drug Dose (m 2) (daily) Days Cycles
Adriamycin 30 mg 1 1 & 2
25mg 1-3 3&4
40mg 1 5&6
30mg 2-3 5 & 6
Vincristine 1.4 mg 1 1-6
L-Asparaginase 10,000 units 1-14 1
Cyclophosphamide 500mg 1 3 & 4
750mg 1 5 & 6
Prednisolone 40mg until CR
ing of greater than 20% was considered positive. Samples
were also tested for terminal deoxynucleotidyl transferase
(TdT) (Bollum, 1979). The results were interpreted according
to the following classification. C-ALL: CD1O', HLA-DR+,
CD19+, CD20-, TdT+, CD7-, surface immunoglobulin
(slg). Null-ALL: CD1O-, HLA-DR+, CD19-, CD20-,
TdT+, CD7-, sIg-. T-ALL: CD1O-, HLA-DR-, CD19-,
CD20-, TdT+, CD7+, sIg-. B-ALL: CDIO-, HLA-DR+,
CD19-, CD20+, TdT-, CD7-, sIg+. The number of patients
in each category is shown in Table I.
Cytogenetic analysis was carried out in 27/54 patients and
was successful in 17. Ten patients were found to have a
normal karyotype, two were Philadelphia chromosome
positive and five had other abnormalities.
Treatment
Details are shown in Figure 1. Ara-C: 2 g m-2, administered
twice daily as a 3-h intravenous infusion for 6 days was given
as the third cycle of treatment after the peripheral blood and
bone marrow had recovered following cycle 2. In the major-
ity of patients, the interval between cycles 2 and 3 was 2
weeks. Ara-C was administered irrespective of whether CR
had been achieved. In 2/9 patients who were over the age of
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Figure I OPAL + H/D ara-C regimen.
50, the dose of ara-C was reduced to 1.5 m-2 b.d. Pred-
nisolone eye drops were prescribed every 2h for 10 days
from the commencement of ara-C.
CNS prophylaxis (in addition to the systemic ara-C) com-
prised intrathecal methotrexate (MTX) 12.5 mg, given as
soon as leukaemic blasts cells had cleared from the peripheral
blood and with each cycle of adriamycin and vincristine
thereafter. Intrathecal MTX or ara-C were subsequently
administered every 2 months for 2 years. No cranial irradia-
tion was given.
Maintenance therapy comprised 6-mercaptopurine daily
and cyclophosphamide and MTX weekly to maintain the
white cell count below 3 x 10' 1, for a total of 3 years.
Supportive care
Patients spent the first and third cycles of treatment in hos-
pital on an open ward. The second, fourth and fifth cycles
were generally given on an outpatient basis. Prophylactic oral
non-absorbable antibiotics (Storring et al., 1977) were pre-
scribed from the onset of treatment. Platelet transfusions
from single donors were given prophylactically to maintain
the platelet count above 20 x 109h1 or if clinically indicated.
Fever was assumed to be bacterial in origin and was treated
with an aminoglycoside/cephaloporin combination in the
first instance.
Definitions
Complete remission (CR) CR required the patient to be in
normal health, with a haemoglobin concentration greater
than Ogdl1-, neutrophils greater than 1.0 x 1091-, and
platelets greater than 100 x 109 1-1; the bone marrow to be
normocellular, with representation of all cell lines in normal
numbers and no leukaemic blast cells; and a CSF cytocentri-
fuge specimen to contain no blast cells.
'Risk' Patients were grouped on the basis of prognostic
factors derived from the previous analysis (Barnett et al.,
1986). 'High risk': T, B, null-ALL or blast count> 10 x
10'1-' at presentation. 'Low risk': C-ALL and blast count
< 10 x 109 1` at presentation.
Statistical analysis
Proportions of patients achieving CR in different prognostic
groups were compared using the x2 test with Yate's correc-
tion (Armitage, 1971). Duration of remission and overall
survival were plotted using standard life table methods (Kap-
lan & Meier, 1958) and compared using the log rank method
(Peto et al., 1977). The significance of prognostic factors in
determining the achievement of CR was evaluated by logistic
regression analysis, whereas duration of CR and overall sur-
vival differences were determined using a stepwise linear
regression method based on Cox's proportional hazards
model (Cox, 1972).
Results
Response to therapy
CR was achieved in 36/54 (67%) patients overall, response
correlating favourably with younger age (15-30 years vs
31-57 years, P = 0.02) and unfavourably with B-cell pheno-
type (P<0.04). The absolute blast count at presentation did
not correlate with response.
CR was achieved before commencing high-dose ara-C in
25/54 patients and subsequently in ten patients. Five of the
latter had overt residual leukaemia before receiving high dose
ara-C; in four of these five, CR was documented after mar-
row recovery following high dose ara-C. The patient who did
not enter CR with high-dose ara-C eventually did so with a
further cycle of adriamycin and vincristine. However, in all
five patients the remissions were short. A further five patients456 A.Z.S. ROHATINER et al.
had no evidence of leukaemia in a regenerating marrow after
cycle 2; CR was subsequently achieved after marrow recovery
following high-dose ara-C. One patient (described below)
never received high-dose ara-C.
Seven patients were considered to have resistant disease
having failed to respond to both the anthracycline containing
cycles and to high-dose ara-C. Eleven patients (aged between
43 and 57) died of infection or bleeding while cytopenic, 7/11
following high-dose ara-C.
Duration ofremission
Thirty-four patients are evaluable: one was withdrawn from
the study after cycle I following a cerebral haemorrhage
presumed to be caused by hypofibrinogenaemia induced by
L-asparaginase. CR was eventually achieved with three cycles
of adriamycin, vincristine and prednisolone but relapse
occurred at 20 months. Another, with B-ALL, electively
received high-dose ara-C and whole body irradiation sup-
ported by autologous bone marrow transplantation (ABMT)
in first remission, the marrow mononuclear cell fraction
being treated in vitro with the monoclonal antibody anti-B1
(anti-CD 20) and rabbit complement (Nadler et al., 1984).
Relapse occurred despite this very intensive consolidation at
3 months. These two patients have therefore been excluded
from the analysis of remission duration.
The median duration of remission was 2 years. Eleven
patients remain free of disease between 3 and 51 years, three
having died in CR. Twenty-two of 36 have relapsed, 20 in
bone marrow (with concurrent CNS relapse in two) and two
in the CNS only. No testicular relapses have occurred.
Remission duration correlated favourably with rapid achieve-
ment of CR, being longer in patients in whom CR was
achieved within 16 days (P=0.03).
Overall, the remission duration curve is the same as that
for patients treated in the previous study. However, there
was a trend in favour of high blast cell count (> 10 x 109
li) and T-cell phenotype (data not shown) in contrast to the
previous results when low blast cell count and C-ALL pheno-
type were found to correlate favourably with duration of
remission (Barnett et al., 1986).
Comparison of remission duration for patients in the 'high'
(Figure 2) or 'low' (Figure 3) risk groups treated either with
the less intensive ('OPAL/HEAV'D') or the more intensive
(OPAL + HD ARA-C) therapy suggests that the prognosis
of patients with 'high risk' disease was improved by intensi-
fication of therapy (P = 0.006). In contrast, patients with
'low risk' disease did not benefit from the addition of high
dose ara-C (P<0.001). Figures 2 and 3 relate to only 31
patients although 34 patients were evaluable for assessment
of remission duration; three patients who entered CR could
not be categorised into the 'high' or 'low' risk groups on the
basis of the monoclonal antibodies used for immunopheno-
typing as described above.
In Figure 2, 7/11 patients who received OPAL + HD ara-C
have relapsed, three died in remission at 28, 31 and 34 days
respectively; only one patient therefore remains in remission.
Survival
The median survival for all 54 patients was 1 year. Three
patients died in CR during hypoplasia associated with high-
dose ara-C. Fifteen patients remain alive (11 in 1st CR, two
in 2nd CR, one in 3rd CR, one in 2nd relapse). The only
factors correlating unfavourably with survival were B-cell
phenotype (P = 0.006) and advanced age (P = 0.01). Second
remission was achieved in only nine of the 22 patients who
relapsed; four of these nine patients have died. Overall, the
survival curve is the same as that observed in the 'control
group' (Figure 4).
Toxicity ofhigh-dose ara-C
This has been described in detail previously (Barnett et al.,
1985). All patients became profoundly neutropenic
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Figure 2 Duration of first remission in relation to treatment
regimen for patients in the 'high risk' group, with confidence
limits (95%) indicated by dotted lines for the 'OPAL/HEAV'D'
treatment.
#' .t* .
20
U
7 0 _ *
pI(;4 Xt, ;t ;-j< *&,~ tI ii; >
!-AL+4DlARA-CN=1' i l ,5 'i.,r '$'>' 5t- P
tl i *Fi 7 iv 0 i ; >Xrsw4=QiE&6, t %.ALA'
.z' '. i i {E \ ;+ * ,. g
n ; i i; e J ~~~~~~~~~~~4 1l4J 2IP>** v' a r1
OPAL + HD'AA- N =1i 1;w;
I.
Figure 3 Duration of first remission in relation to treatment
regimen for patients in the 'low risk' group, with confidence
limits (95%) indicated by dotted lines for the 'OPAL/HEAV'D'
treatment.
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Figure 4 Overall survival for the two treatment regimens.
(<0.5 x 1091-') and spent approximately 4 weeks in hospi-
tal. Seven of the 11 'early deaths' occurred following high-
dose ara-C and three other patients (all in the 'low' risk
group) died while receiving the drug as consolidation
therapy. Virtually all patients experienced some degree of
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nausea and vomiting and more than half, an erythematous
skin reaction which was most marked on the hands and feet.
A few patients complained of ocular discomfort despite the
regular use of Prednisolone eye drops. Neurological toxicity
was manifest as nystagmus (one patient), tremor (two
patients) and grand mal fits associated with transient CT
scan abnormalities in one patient as described previously
(Barnett et al., 1985a).
Discussion
This study was undertaken to determine whether the incor-
poration of high-dose ara-C into the treatment of adults with
ALL would improve the prognosis and at the same time
obviate the need for cranial irradiation as central nervous
system prophylaxis. Three years after entry ofthe last patient
it transpires that a selected group of patients may have
benefited, although at considerable cost, the treatment having
appreciable morbidity and significant mortality.
The CR rate was not improved overall despite the fact that
remission was achieved with high-dose ara-C in 4/10 patients
who had persistent leukaemia following two cycles of con-
ventional therapy. This may in part be a consequence of the
number of early deaths and a relatively older patient popula-
tion than that treated previously. Alternatively, ara-C may
predominantly be effective in the same group of patients as
those who respond to conventional therapy. The literature on
the subject is divided; CR rates for patients with 'resistant'
disease range from 8/30 (27%) with high-dose ara-C alone
(Kantarjian et al., 1986) to 10/13 (77%) when it is given in
combination with other drugs (Peters et al., 1987). Perhaps of
more importance is the fact that none of these 'salvage'
remissions achieved with ara-C were durable.
Likewise, there was no difference in overall survival or
duration of first remission between the whole group of
patients in the current study and the historical control group.
However, the addition of high-dose ara-C does appear to
have improved the prognosis of patients with 'poor risk'
prognostic factors, i.e. those with a high blast cell count
(Barnett et al., 1986; Amadori et al., 1980; Baccarani et al.,
1982; Gingrich et al., 1985; Lazzarino et al., 1982; Marcus et
al., 1986; Clarkson et al., 1985) and those with T-cell ALL
(Bitran, 1978; Baccarani et al., 1983; Lister et al., 1979).
These results are consistent with the findings of two large
studies in which the use of intensive remission induction and
consolidation therapy has resulted in patients with T-ALL
having a better prognosis than those with C-ALL (Clarkson
et al., 1985; Hoelzer et al., 1988). Both treatment pro-
grammes include ara-C but not in very high doses; since
T-lymphoblasts are highly sensitive to ara-C in vitro and
retain ara-CTP to a greater degree than lymphoblasts of B
lineage (Plunkett et al., 1987), the improvement may be due
specifically to the inclusion of ara-C rather than to an inc-
rease in the intensity of the therapy overall.
While the prognosis ofpatients with 'high risk' disease was
improved, patients with 'low risk' disease fared worse. The
reasons for this are not clear; the delay in administering cycle
4 incurred by the prolonged cytopenia following high-dose
ara-C may have allowed resistance to develop, pre-disposing
to early relapse.
As yet, there has been no obvious increase in the rate of
isolated CNS relapse consequent on the omission of cranial
irradiation although further follow up is required for this to
be affirmed with confidence.
Caution must be exercised in the interpretation of these
results. First, the observations were made on a small number
of patients and comparisons made with historical controls.
Second, the advantage of the intensive therapy was only in
terms of duration of first remission, with only a trend in its
favour for disease free survival because of the mortality
related to a treatment which also caused considerable mor-
bidity. However, these results support individualisation of
therapy for adults with ALL on the basis of prognostic
factor analysis. High dose ara-C may have a role as con-
solidation therapy in younger adults expected to be at high
risk for relapse with conventional therapy. It is unlikely to
play a major role for the remainder. It remains to be deter-
mined whether different schedules of ara-C at lower doses are
as effective.
We are very pleased to acknowledge the contribution of the medical
and nursing staff and very grateful to Claire Parfitt for preparing and
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